Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1906 1
1917 1
1936 1
1945 2
1947 1
1948 4
1949 2
1950 3
1951 6
1952 9
1953 6
1954 7
1955 11
1956 5
1957 5
1958 8
1959 6
1960 8
1961 4
1962 9
1963 4
1964 11
1965 7
1966 3
1967 4
1968 1
1970 5
1971 6
1972 6
1973 7
1974 9
1975 31
1976 35
1977 30
1978 32
1979 41
1980 60
1981 84
1982 89
1983 80
1984 106
1985 137
1986 140
1987 124
1988 123
1989 144
1990 172
1991 168
1992 187
1993 172
1994 245
1995 239
1996 238
1997 237
1998 227
1999 231
2000 273
2001 272
2002 312
2003 323
2004 324
2005 283
2006 281
2007 308
2008 310
2009 328
2010 374
2011 414
2012 528
2013 546
2014 649
2015 730
2016 790
2017 731
2018 753
2019 872
2020 977
2021 843
2022 551
2023 466
2024 195

Text availability

Article attribute

Article type

Publication date

Search Results

14,540 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for thrombokinase
Search for thrombocinase instead (2 results)
Factor Xa: Thrombokinase from Paul Morawitz to J Haskell Milstone.
Milstone LM. Milstone LM. J Thromb Thrombolysis. 2021 Aug;52(2):364-370. doi: 10.1007/s11239-021-02387-6. Epub 2021 Jan 23. J Thromb Thrombolysis. 2021. PMID: 33484373 Review.
In 1904 Paul Morawitz postulated that an enzyme, which he named thrombokinase, would be the primary activator of prothrombin. Fifty years passed before J Haskell Milstone isolated, purified and functionally characterized the enzyme we now call Factor Xa. This …
In 1904 Paul Morawitz postulated that an enzyme, which he named thrombokinase, would be the primary activator of prothrombin. Fifty y …
Preparation of thrombokinase from bovine plasma.
MILSTONE JH. MILSTONE JH. J Gen Physiol. 1959 Mar 20;42(4):665-76. doi: 10.1085/jgp.42.4.665. J Gen Physiol. 1959. PMID: 13631194 Free PMC article.
In parallel tests, the product appears to be more active than its parent plasma, although it contains only 0.002 per cent of the nitrogen. However, the thrombokinase of the product has been activated, whereas the thrombokinase of the plasma is probably in an inactiv …
In parallel tests, the product appears to be more active than its parent plasma, although it contains only 0.002 per cent of the nitrogen. H …
Thrombokinase of the blood as trypsin-like enzyme.
MILSTONE JH. MILSTONE JH. J Gen Physiol. 1962 Mar;45(4)Pt2(4):103-13. doi: 10.1085/jgp.45.4.103. J Gen Physiol. 1962. PMID: 14035995 Free PMC article.
Chromatography on DEAE-cellulose separated thrombin from thrombokinase. The TAMe esterase associated with the thrombokinase fractions was largely suppressed by soybean trypsin inhibitor, while that associated with the thrombin fractions was not. Highly purified t …
Chromatography on DEAE-cellulose separated thrombin from thrombokinase. The TAMe esterase associated with the thrombokinase fr …
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, Mathur VS, Castillo J, Bronson MD, Leeds JM, Mar FA, Gold A, Crowther MA. Siegal DM, et al. N Engl J Med. 2015 Dec 17;373(25):2413-24. doi: 10.1056/NEJMoa1510991. Epub 2015 Nov 11. N Engl J Med. 2015. PMID: 26559317 Free article. Clinical Trial.
BACKGROUND: Bleeding is a complication of treatment with factor Xa inhibitors, but there are no specific agents for the reversal of the effects of these drugs. ...The primary outcome was the mean percent change in anti-factor Xa activity, which is a me …
BACKGROUND: Bleeding is a complication of treatment with factor Xa inhibitors, but there are no specific agents for the revers …
Effect of blood thrombokinase, as influenced by soy bean trypsin inhibitor, ultracentrifugation, and accessory factors.
MILSTONE JH. MILSTONE JH. J Gen Physiol. 1955 Jul 20;38(6):757-69. doi: 10.1085/jgp.38.6.757. J Gen Physiol. 1955. PMID: 13242762 Free PMC article.
In this system, no thrombin was produced without thrombokinase. On the other hand, thrombin was produced from prothrombin and thrombokinase, even when all the other reagents were omitted. ...Quantitative tests indicated that the "accelerator" reagent exerted an effe …
In this system, no thrombin was produced without thrombokinase. On the other hand, thrombin was produced from prothrombin and thro …
OUTSTANDING CHARACTERISTICS OF THROMBOKINASE ISOLATED FROM BOVINE PLASMA.
MILSTONE JH, OULIANOFF N, MILSTONE VK. MILSTONE JH, et al. J Gen Physiol. 1963 Nov;47(2):315-27. doi: 10.1085/jgp.47.2.315. J Gen Physiol. 1963. PMID: 14080818 Free PMC article.
A few micrograms of thrombokinase per milliliter can activate prothrombin in the presence of EDTA. A few thousandths of a microgram causes rapid production of thrombin in the system: prothrombin, thrombokinase, calcium chloride, phosphatide, "accelerator." But, t …
A few micrograms of thrombokinase per milliliter can activate prothrombin in the presence of EDTA. A few thousandths of a microgram c …
Andexanet Alfa or Prothrombin Complex Concentrate for Factor Xa Inhibitor Reversal in Acute Major Bleeding: A Systematic Review and Meta-Analysis.
Nederpelt CJ, Naar L, Krijnen P, le Cessie S, Kaafarani HMA, Huisman MV, Velmahos GC, Schipper IB. Nederpelt CJ, et al. Crit Care Med. 2021 Oct 1;49(10):e1025-e1036. doi: 10.1097/CCM.0000000000005059. Crit Care Med. 2021. PMID: 33967205
OBJECTIVES: To combine evidence on andexanet alfa and prothrombin complex concentrates for factor Xa inhibitor-associated bleeding to guide clinicians on reversal strategies. ...STUDY SELECTION: Observational studies and randomized clinical trials studying hemostati …
OBJECTIVES: To combine evidence on andexanet alfa and prothrombin complex concentrates for factor Xa inhibitor-associated blee …
Andexanet Alfa: First Global Approval.
Heo YA. Heo YA. Drugs. 2018 Jul;78(10):1049-1055. doi: 10.1007/s40265-018-0940-4. Drugs. 2018. PMID: 29926311 Free PMC article. Review.
Intravenous andexanet alfa [coagulation factor Xa (recombinant), inactivated-zhzo; Andexxa()] is a first-in-class recombinant modified factor Xa protein that has been developed by Portola Pharmaceuticals as a universal antidote to reverse anticoagulant …
Intravenous andexanet alfa [coagulation factor Xa (recombinant), inactivated-zhzo; Andexxa()] is a first-in-class recombinant …
Xa receptor EPR-1.
Altieri DC. Altieri DC. FASEB J. 1995 Jul;9(10):860-5. doi: 10.1096/fasebj.9.10.7615156. FASEB J. 1995. PMID: 7615156 Review.
This process occurs on vascular cell surfaces through the ability of the coagulation protease factor Xa to generate thrombin. However, experimental evidence accumulated during the past decade underscores how prothrombin activation is only one of the biological conse …
This process occurs on vascular cell surfaces through the ability of the coagulation protease factor Xa to generate thrombin. …
[On standardization of thrombokinase].
SCHMID J. SCHMID J. Acta Haematol. 1950 Nov;4(5):265-72. doi: 10.1159/000203762. Acta Haematol. 1950. PMID: 14789449 Undetermined Language. No abstract available.
14,540 results
You have reached the last available page of results. Please see the User Guide for more information.